Global Blood Therapeutics Garners $48,000,000 Series B Funding Round

  • Feed Type
  • Date
    1/6/2015
  • Company Name
    Global Blood Therapeutics
  • Mailing Address
    400 East Jamie Court South San Francisco, CA 94080 USA
  • Company Description
    Global Blood Therapeutics, Inc. is a product-focused company building a pipeline of innovative, oral medicines to revolutionize the treatment of chronic blood-based diseases and severe genetic disorders for which there are currently no cures available and only extremely limited therapeutic options.
  • Website
    http://www.globalbloodtx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $48,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to advance the company’s lead drug candidate, GBT440, for the treatment of sickle cell disease (SCD). GBT440 has shown promising results in preclinical testing and the company is initiating a Phase I/II clinical trial.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy